# EDGAR Filing Document

**Accession Number:** 0001651311
**File Stem:** 0001193125-25-302551
**Filing Date:** 2025-11
**Character Count:** 8331
**Document Hash:** b8f3f92043a1fabfb5f50da37fb3132f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-302551.hdr.sgml**: 20251128

**ACCESSION NUMBER**: 0001193125-25-302551

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251125

**FILED AS OF DATE**: 20251128

**DATE AS OF CHANGE**: 20251128

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Shuman Harry
- **CENTRAL INDEX KEY:** 0001791115

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37773
- **FILM NUMBER:** 251535867

**MAIL ADDRESS:**
- **STREET 1:** C/O MERUS N.V.
- **STREET 2:** VALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merus N.V.
- **CENTRAL INDEX KEY:** 0001651311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE
- **BUSINESS PHONE:** 31 030 253 8800

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merus B.V.
- **DATE OF NAME CHANGE:** 20150819

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Shuman Harry<br><sub>(Last) (First) (Middle)</sub><br>C/O MERUS N.V.<br>UPPSALALAAN 17<br><sub>(Street)</sub><br>UTRECHT, P7 3584 CT<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-25 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_VP Controller, PAO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Merus N.V. [ MRUS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares | 2025-11-25 |  | M |  | 800 | A | <sup>(1)</sup> | 11802 | D |  |
| Common Shares | 2025-11-25 |  | M |  | 1000 | A | <sup>(2)</sup> | 12802 | D |  |
| Common Shares | 2025-11-25 |  | M |  | 1800 | A | <sup>(3)</sup> | 14602 | D |  |
| Common Shares | 2025-11-25 |  | M |  | 2200 | A | <sup>(4)</sup> | 16802 | D |  |
| Common Shares | 2025-11-25 |  | M |  | 1500 | A | <sup>(5)</sup> | 18302 | D |  |
| Common Shares | 2025-11-25 |  | M |  | 1000 | A | <sup>(6)</sup> | 19302 | D |  |
| Common Shares | 2025-11-25 |  | S |  | 8300 | D | $95.92 | 11002 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | 18.61<sup>(1)</sup> | 2025-11-25 |  | M |  |  | 800 | <sup>(7)</sup> | 2030-02-14 | Common Shares | 800 | $0 | 8400 | D |  |
| Share Option (right to buy) | 24.61<sup>(2)</sup> | 2025-11-25 |  | M |  |  | 1000 | <sup>(8)</sup> | 2032-01-31 | Common Shares | 1000 | $0 | 16000 | D |  |
| Share Option (right to buy) | 13.23<sup>(3)</sup> | 2025-11-25 |  | M |  |  | 1800 | <sup>(9)</sup> | 2029-06-06 | Common Shares | 1800 | $0 | 4700 | D |  |
| Share Option (right to buy) | 24.43<sup>(4)</sup> | 2025-11-25 |  | M |  |  | 2200 | <sup>(10)</sup> | 2031-02-16 | Common Shares | 2200 | $0 | 13300 | D |  |
| Share Option (right to buy) | 20.15<sup>(5)</sup> | 2025-11-25 |  | M |  |  | 1500 | <sup>(11)</sup> | 2031-06-02 | Common Shares | 1500 | $0 | 5000 | D |  |
| Share Option (right to buy) | 16.07<sup>(6)</sup> | 2025-11-25 |  | M |  |  | 1000 | <sup>(12)</sup> | 2033-02-02 | Common Shares | 1000 | $0 | 14500 | D |  |

---

### Footnotes:

(1) Represents the exercise price of the options originally granted on February 14, 2020.

(2) Represents the exercise price of the options originally granted on January 31, 2022.

(3) Represents the exercise price of the options originally granted on June 6, 2019.

(4) Represents the exercise price of the options originally granted on February 16, 2021.

(5) Represents the exercise price of the options originally granted on June 2, 2021.

(6) Represents the exercise price of the options originally granted on February 2, 2023.

(7) Options vest over a four-year period from January 1, 2020. 25% vest on January 1, 2021 and in 36 equal monthly installments thereafter.

(8) Options vest over a four-year period from January 1, 2022. 25% vest on January 1, 2023 and in 36 equal monthly installments thereafter.

(9) Options vest over a four-year period from April 22, 2019. 25% vest on April 22, 2020 and in 36 equal monthly installments thereafter.

(10) Options vest over a four-year period from January 1, 2021. 25% vest on January 1, 2022 and in 36 equal monthly installments thereafter.

(11) Options vest over a four-year period commencing May 28, 2021. 25% vest after one year and in 36 equal monthly installments thereafter.

(12) Options vest over a four-year period from January 1, 2023. 25% vest on January 1, 2024 and in 36 equal monthly installments thereafter.

**Signature:** /s/ Peter Silverman as attorney-in-fact  
**Date:** 2025-11-28

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**